menu
    • menu
    [{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Anlotinib","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Children's Cancer Group, China","sponsor":"Shanghai Children's Medical Center | Nanjing Children's Hospital | Qilu Hospital of Shandong University | Tianjin Cancer Hospital | West China Second University Hospital | Xiangya Hospital | 1st Affiliated Hospital of Zhengzhou University | Shenzhen Child","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pregabalin","moa":"||Voltage-gated calcium channel","graph1":"Oncology","graph2":"Phase III","graph3":"Children's Cancer Group, China","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrathecal","sponsorNew":"Children's Cancer Group, China \/ Shanghai Children's Medical Center | Nanjing Children's Hospital | Qilu Hospital of Shandong University | Tianjin Cancer Hospital | West China Second University Hospital | Xiangya Hospital | 1st Affiliated Hospital of Zhengzhou University | Shenzhen Child","highestDevelopmentStatusID":"10","companyTruncated":"Children's Cancer Group, China \/ Shanghai Children's Medical Center | Nanjing Children's Hospital | Qilu Hospital of Shandong University | Tianjin Cancer Hospital | West China Second University Hospital | Xiangya Hospital | 1st Affiliated Hospital of Zhengzhou University | Shenzhen Child"},{"orgOrder":0,"company":"Henlius","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Henlius","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Henlius \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Henlius \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Chia Tai Tianqing Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Anlotinib","moa":"||PD-1","graph1":"Oncology","graph2":"Phase IV","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Peking Union Medical College Hospital \/ Chia Tai Tianqing Pharmaceutical Group","highestDevelopmentStatusID":"11","companyTruncated":"Peking Union Medical College Hospital \/ Chia Tai Tianqing Pharmaceutical Group"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"GWT-TUD","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"GWT-TUD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"GWT-TUD \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"GWT-TUD \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"BeOne Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeOne Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"F. Hoffmann-La Roche \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Biotheus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Biotheus","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/ Biotheus"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeOne Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeOne Medicines \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"BNT327","moa":"||PD-L1\/VEGF-A","graph1":"Oncology","graph2":"Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lee Pharma \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lee Pharma \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2025","type":"Partnership","leadProduct":"BNT327","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Biotheus","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2025","type":"Acquisition","leadProduct":"Carboplatin","moa":"||PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biotheus \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Biotheus \/ BioNTech"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Crescent Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apollomics Inc \/ GlycoMimetics","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ GlycoMimetics"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Apollomics Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Crescent Biopharma \/ Apollomics Inc","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Apollomics Inc"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Crescent Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Crescent Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Crescent Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Crescent Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Crescent Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Rachel Sanborn","sponsor":"AstraZeneca | Earle A. Chiles Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Rachel Sanborn","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Rachel Sanborn \/ AstraZeneca | Earle A. Chiles Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Rachel Sanborn \/ AstraZeneca | Earle A. Chiles Research Institute"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Weill Medical College of Cornell University \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Weill Medical College of Cornell University \/ Genentech"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"BeOne Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BeOne Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"||B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"You Lu","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"You Lu","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"You Lu \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"You Lu \/ AstraZeneca"},{"orgOrder":0,"company":"University of Southampton","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"University of Southampton","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"University of Southampton \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"University of Southampton \/ Merck & Co"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Qilu Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Qilu Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nanfang Hospital, Southern Medical University","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adebrelimab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Nanfang Hospital, Southern Medical University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nanfang Hospital, Southern Medical University \/ Suzhou Suncadia Biopharmaceuticals Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Nanfang Hospital, Southern Medical University \/ Suzhou Suncadia Biopharmaceuticals Co., Ltd."},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"BNT327","moa":"||PD-L1\/VEGF-A","graph1":"Oncology","graph2":"Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"Jeffrey Clarke","sponsor":"Genentech | Duke University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Jeffrey Clarke","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Jeffrey Clarke \/ Genentech | Duke University","highestDevelopmentStatusID":"8","companyTruncated":"Jeffrey Clarke \/ Genentech | Duke University"},{"orgOrder":0,"company":"Gruppo Oncologico Italiano di Ricerca Clinica","sponsor":"F. Hoffmann-La Roche | YGHEA, CRO Division of Ecol Studio spa | Luca Boni","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etoposide","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Gruppo Oncologico Italiano di Ricerca Clinica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Gruppo Oncologico Italiano di Ricerca Clinica \/ F. Hoffmann-La Roche | YGHEA, CRO Division of Ecol Studio spa | Luca Boni","highestDevelopmentStatusID":"8","companyTruncated":"Gruppo Oncologico Italiano di Ricerca Clinica \/ F. Hoffmann-La Roche | YGHEA, CRO Division of Ecol Studio spa | Luca Boni"},{"orgOrder":0,"company":"Trans Tasman Radiation Oncology Group","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etoposide","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Trans Tasman Radiation Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Trans Tasman Radiation Oncology Group \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Trans Tasman Radiation Oncology Group \/ AstraZeneca"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Microtubule","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Biostar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK-4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK-4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK-4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Taizhou HoudeAoke Biomedical Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Taizhou HoudeAoke Biomedical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taizhou HoudeAoke Biomedical Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Taizhou HoudeAoke Biomedical Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"||B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Leads Biolabs \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ATG-010","moa":"||XPO1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||B-lymphocyte antigen CD20 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Taofeek Owonikoko","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"Taofeek Owonikoko","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taofeek Owonikoko \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Taofeek Owonikoko \/ AstraZeneca"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Crescent Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apollomics Inc \/ GlycoMimetics","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ GlycoMimetics"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ City of Hope"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ City of Hope"},{"orgOrder":0,"company":"Yunpeng Liu","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Adebrelimab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Yunpeng Liu","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Yunpeng Liu \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Yunpeng Liu \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Undisclosed","graph2":"Phase II","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Peking University People's Hospital \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Peking University People's Hospital \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Aaron Logan","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"||Tyrosine-protein kinase JAK1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aaron Logan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aaron Logan \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Aaron Logan \/ Incyte Corporation"},{"orgOrder":0,"company":"Princess Maxima Center for Pediatric Oncology","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||Stem cell growth factor receptor | Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor RET | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Princess Maxima Center for Pediatric Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Princess Maxima Center for Pediatric Oncology \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"Princess Maxima Center for Pediatric Oncology \/ Daiichi Sankyo"},{"orgOrder":0,"company":"St. Jude Children's Research Hospital","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Entrectinib","moa":"||Proto-oncogene tyrosine-protein kinase ROS | Neurotrophic tyrosine kinase receptor | ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase II","graph3":"St. Jude Children's Research Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"St. Jude Children's Research Hospital \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"St. Jude Children's Research Hospital \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Eric Jacobsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"||Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase II","graph3":"Eric Jacobsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eric Jacobsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Eric Jacobsen \/ Ipsen"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ponatinib","moa":"||Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"St. Jude Children's Research Hospital","sponsor":"Incyte Corporation | North American Consortium for Histiocytosis | Cures Within Reach","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"||Tyrosine-protein kinase JAK1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"St. Jude Children's Research Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"St. Jude Children's Research Hospital \/ Incyte Corporation | North American Consortium for Histiocytosis | Cures Within Reach","highestDevelopmentStatusID":"7","companyTruncated":"St. Jude Children's Research Hospital \/ Incyte Corporation | North American Consortium for Histiocytosis | Cures Within Reach"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"Indiana University","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"||VEGFR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indiana University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Indiana University \/ Exelixis","highestDevelopmentStatusID":"7","companyTruncated":"Indiana University \/ Exelixis"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Surufatinib","moa":"||VEGF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Canakinumab","moa":"||Interleukin-1 beta","graph1":"Oncology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Dactinomycin","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Children's Oncology Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"OncoHost","sponsor":"Hengenix Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"OncoHost","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoHost \/ Hengenix Biotech","highestDevelopmentStatusID":"10","companyTruncated":"OncoHost \/ Hengenix Biotech"},{"orgOrder":0,"company":"Shanghai Pulmonary Hospital","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Pulmonary Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Pulmonary Hospital \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Pulmonary Hospital \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2020","type":"Funding","leadProduct":"Vincristine Sulfate","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"University of Birmingham","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Birmingham \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"University of Birmingham \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"G1 Therapeutics, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase IV","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ G1 Therapeutics, Inc","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ G1 Therapeutics, Inc"},{"orgOrder":0,"company":"Children's Cancer Group, China","sponsor":"Shanghai Children's Medical Center | Beijing Children's Hospital | Children's Hospital of Scow University | West China Second University Hospital | Nanjing Children's Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Inst","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Prednisone","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Children's Cancer Group, China","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Cancer Group, China \/ Shanghai Children's Medical Center | Beijing Children's Hospital | Children's Hospital of Scow University | West China Second University Hospital | Nanjing Children's Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Inst","highestDevelopmentStatusID":"10","companyTruncated":"Children's Cancer Group, China \/ Shanghai Children's Medical Center | Beijing Children's Hospital | Children's Hospital of Scow University | West China Second University Hospital | Nanjing Children's Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Inst"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crescent Biopharma \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"18-F Fludeoxyglucose","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"Children's Oncology Group \/ National Cancer Institute"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BMS986012","moa":"||OX40 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Children's Cancer Group, China","sponsor":"Shanghai Children's Medical Center | Najing Children's Hospital | West China Second University Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Institute and Hospital | Tongji Hospital | Xiangya Hospital, Central South U","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Children's Cancer Group, China","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Children's Cancer Group, China \/ Shanghai Children's Medical Center | Najing Children's Hospital | West China Second University Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Institute and Hospital | Tongji Hospital | Xiangya Hospital, Central South U","highestDevelopmentStatusID":"9","companyTruncated":"Children's Cancer Group, China \/ Shanghai Children's Medical Center | Najing Children's Hospital | West China Second University Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Institute and Hospital | Tongji Hospital | Xiangya Hospital, Central South U"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AL3810","moa":"||VEGFR\/PDGFR\/FGFR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"18-F Fludeoxyglucose","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Children's Oncology Group \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BMS-986012","moa":"||Fucosyl-GM1","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Czech Lymphoma Study Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Czech Lymphoma Study Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Czech Lymphoma Study Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Czech Lymphoma Study Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Genentech"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Hirva Mamdani","sponsor":"AstraZeneca | Barbara Ann Karmanos Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Hirva Mamdani","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hirva Mamdani \/ AstraZeneca | Barbara Ann Karmanos Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Hirva Mamdani \/ AstraZeneca | Barbara Ann Karmanos Cancer Institute"},{"orgOrder":0,"company":"Yale University","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Mogamulizumab","moa":"||C-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Kyowa Kirin","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ Kyowa Kirin"},{"orgOrder":0,"company":"Centre L\u00e9on B\u00e9rard","sponsor":"Groupe Francais De Pneumo-Cancerologie","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Centre L\u00e9on B\u00e9rard","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre L\u00e9on B\u00e9rard \/ Groupe Francais De Pneumo-Cancerologie","highestDevelopmentStatusID":"8","companyTruncated":"Centre L\u00e9on B\u00e9rard \/ Groupe Francais De Pneumo-Cancerologie"},{"orgOrder":0,"company":"Gruppo Oncologico Italiano di Ricerca Clinica","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Gruppo Oncologico Italiano di Ricerca Clinica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gruppo Oncologico Italiano di Ricerca Clinica \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Gruppo Oncologico Italiano di Ricerca Clinica \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Children's Oncology Group \/ National Cancer Institute"},{"orgOrder":0,"company":"University of Washington","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"University of Washington \/ AstraZeneca"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Children's Oncology Group \/ National Cancer Institute"},{"orgOrder":0,"company":"Muhammad Furqan","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Muhammad Furqan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Muhammad Furqan \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Muhammad Furqan \/ AstraZeneca"},{"orgOrder":0,"company":"University of Washington","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"University of Washington \/ AstraZeneca"},{"orgOrder":0,"company":"University of Washington","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University of Washington \/ Incyte Corporation"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Children's Oncology Group \/ Inapplicable"},{"orgOrder":0,"company":"Joseph Tuscano","sponsor":"National Cancer Institute | ADC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Joseph Tuscano","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joseph Tuscano \/ National Cancer Institute | ADC Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Joseph Tuscano \/ National Cancer Institute | ADC Therapeutics"},{"orgOrder":0,"company":"Vanderbilt-Ingram Cancer Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Vanderbilt-Ingram Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt-Ingram Cancer Center \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Vanderbilt-Ingram Cancer Center \/ Merck & Co"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Children's Oncology Group \/ Inapplicable"},{"orgOrder":0,"company":"University of Washington","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi","moa":"||Asparagine","graph1":"Oncology","graph2":"Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"University of Washington \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Biotheus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biotheus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biotheus \/ Inapplicable"},{"orgOrder":0,"company":"Xiangya Hospital, Central South University","sponsor":"Chia Tai Tianqing Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etoposide","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Xiangya Hospital, Central South University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiangya Hospital, Central South University \/ Chia Tai Tianqing Pharmaceutical Group","highestDevelopmentStatusID":"8","companyTruncated":"Xiangya Hospital, Central South University \/ Chia Tai Tianqing Pharmaceutical Group"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Jiangsu Hengrui Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etoposide","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Jiangsu Hengrui Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Jiangsu Hengrui Pharmaceutical"},{"orgOrder":0,"company":"Institut Curie","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Institut Curie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Curie \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Institut Curie \/ Pfizer Inc"},{"orgOrder":0,"company":"St. Jude Children's Research Hospital","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"St. Jude Children's Research Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children's Research Hospital \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"St. Jude Children's Research Hospital \/ AbbVie Inc"},{"orgOrder":0,"company":"Shanghai Chest Hospital","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etoposide","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Chest Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Chest Hospital \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Chest Hospital \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"||Granulocyte colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fondazione Italiana Linfomi","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fondazione Italiana Linfomi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fondazione Italiana Linfomi \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Fondazione Italiana Linfomi \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Etoposide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leads Biolabs \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Inapplicable"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leads Biolabs \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DLL3\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"National Cancer Institute | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ National Cancer Institute | AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ National Cancer Institute | AstraZeneca"},{"orgOrder":0,"company":"Vanderbilt-Ingram Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vanderbilt-Ingram Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt-Ingram Cancer Center \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Vanderbilt-Ingram Cancer Center \/ Genentech"},{"orgOrder":0,"company":"OHSU Knight Cancer Institute","sponsor":"Genentech | Oregon Health and Science University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OHSU Knight Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OHSU Knight Cancer Institute \/ Genentech | Oregon Health and Science University","highestDevelopmentStatusID":"7","companyTruncated":"OHSU Knight Cancer Institute \/ Genentech | Oregon Health and Science University"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabeled Compounds","year":"2021","type":"Inapplicable","leadProduct":"177-Lu DOTA-TATE","moa":"||SSTR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Chongqing University Cancer Hospital","sponsor":"Fundamenta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CAR-T-19A","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing University Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing University Cancer Hospital \/ Fundamenta Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing University Cancer Hospital \/ Fundamenta Therapeutics"},{"orgOrder":0,"company":"University of Washington","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"University of Washington \/ Genentech"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zhou Chengzhi","sponsor":"Jiangsu Hengrui Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Apatinib","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Zhou Chengzhi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhou Chengzhi \/ Jiangsu Hengrui Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Zhou Chengzhi \/ Jiangsu Hengrui Pharmaceutical"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AK112","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"ADC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Carmustine","moa":"||RNA | DNA | Glutathione reductase","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ ADC Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ ADC Therapeutics"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BI 764532","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tianjin Medical University Cancer Institute and Hospital","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitoxantrone","moa":"||DNA topoisomerase II alpha | DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Tianjin Medical University Cancer Institute and Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Medical University Cancer Institute and Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Tianjin Medical University Cancer Institute and Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RayzeBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"RayzeBio \/ Inapplicable"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Qihan Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang University \/ Qihan Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Qihan Biotech"},{"orgOrder":0,"company":"Fundamenta Therapeutics","sponsor":"The First Affiliated Hospital of Zhengzhou University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CAR-T-19A","moa":"||CD19","graph1":"Undisclosed","graph2":"Phase I","graph3":"Fundamenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundamenta Therapeutics \/ The First Affiliated Hospital of Zhengzhou University","highestDevelopmentStatusID":"6","companyTruncated":"Fundamenta Therapeutics \/ The First Affiliated Hospital of Zhengzhou University"},{"orgOrder":0,"company":"Henan Cancer Hospital","sponsor":"Fundamenta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CAR-T-19A","moa":"||CD19","graph1":"Undisclosed","graph2":"Phase I","graph3":"Henan Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Henan Cancer Hospital \/ Fundamenta Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Henan Cancer Hospital \/ Fundamenta Therapeutics"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Qihan Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang University \/ Qihan Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Qihan Biotech"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Qihan Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang University \/ Qihan Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Qihan Biotech"}]

    Find Clinical Drug Pipeline Developments & Deals for Baxter Oncology Brand of Etoposide

    Menu

    Baxter Oncology Brand of Etoposide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lee Pharma

                            India
                            CPhI WW Frankfurt
                            Booth #11.1C68
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

                            Lead Product(s) : Socazolimab,Carboplatin,Etoposide

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Sorrento Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sorrento's License Partner, Lee's Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Soc...

                            Details : ZKAB001 (Socazolimab) (anti-PD-L1 monoclonal antibody) was discovered by Sorrento from its fully human antibody G-MABTM library and licensed by China Oncology Focus Limited (“COF”), a Lee’s Pharm subsidiary, for the Great China Territories.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 17, 2022

                            Lead Product(s) : Socazolimab,Carboplatin,Etoposide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Sorrento Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lee Pharma

                            India
                            CPhI WW Frankfurt
                            Booth #11.1C68
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

                            Lead Product(s) : Socazolimab,Carboplatin,Etoposide

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Sorrento Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lee’s 1st Patient Dosed Socazolimab, Licensed From Sorrento Treatment Cancer

                            Details : The initiation of this Phase 3 trial is based on the very encouraging results from an earlier Phase Ib trial in which Socazolimab combined with carboplatin and etoposide showed a promising efficacy and safety profile in patients with extensive-stage smal...

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 23, 2021

                            Lead Product(s) : Socazolimab,Carboplatin,Etoposide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Sorrento Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lee Pharma

                            India
                            CPhI WW Frankfurt
                            Booth #11.1C68
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

                            Lead Product(s) : ZKAB001,Carboplatin,Etoposide

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 07, 2021

                            Lead Product(s) : ZKAB001,Carboplatin,Etoposide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lee Pharma

                            India
                            CPhI WW Frankfurt
                            Booth #11.1C68
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

                            Lead Product(s) : ZKAB001,Carboplatin,Etoposide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 15, 2020

                            Lead Product(s) : ZKAB001,Carboplatin,Etoposide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sanofi

                            France
                            ChemOutsourcing
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Isatuximab,Dexamethasone,Fludarabine Phosphate,Cytarabine,Daunorubicin,Idarubicin Hydrochloride,Filgrastim,Mitoxantrone,Doxorubicin Hydrochloride,Vincristine Sulfate,Peg L asparaginase,Cyclophosphamide,Etoposide,Methotrexate,L - Asparaginase,Hydroxyurea

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 04, 2019

                            Lead Product(s) : Isatuximab,Dexamethasone,Fludarabine Phosphate,Cytarabine,Daunorubicin,Idarubicin Hydrochloride,Filgrastim,Mitoxantrone,Doxorubicin Hydrochloride,Vincristine Sulfate,Peg L asparaginase,Cyclophosphamide,Etoposide,Methotrexate,L - Asparaginase,Hydroxyurea

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AbbVie Inc

                            U.S.A
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexamethasone,Vincristine Sulfate,Pegasparaginase,Cytarabine,Etoposide,Azacitidine,Decitabine,Rituximab,Cyclophosphamide,Topotecan Hydrochloride,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Genentech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed o...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            August 02, 2017

                            Lead Product(s) : Dexamethasone,Vincristine Sulfate,Pegasparaginase,Cytarabine,Etoposide,Azacitidine,Decitabine,Rituximab,Cyclophosphamide,Topotecan Hydrochloride,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Genentech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AbbVie Inc

                            U.S.A
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Veliparib,Carboplatin,Etoposide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 13, 2014

                            Lead Product(s) : Veliparib,Carboplatin,Etoposide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Pharmacyclics

                            U.S.A
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibrutinib,Etoposide,Prednisone,Doxorubicin Hydrochloride,Cyclophosphamide,Vincristine Sulfate,Rituximab,Pegfilgrastim

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Celgene Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cel...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 20, 2014

                            Lead Product(s) : Ibrutinib,Etoposide,Prednisone,Doxorubicin Hydrochloride,Cyclophosphamide,Vincristine Sulfate,Rituximab,Pegfilgrastim

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Celgene Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie company banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            BioNTech

                            Germany arrow
                            EPSC
                            Not Confirmed

                            BioNTech

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNT327,Etoposide,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $11,100.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            BioNTech and BMS Partner to Develop Bispecific Antibody BNT327 for Solid Tumors

                            Details : The partnership aims to expand BioNTech’s BNT327, a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A, is currently being evaluated in 1L-treatment in extensive stage SCLC.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : $1500 million

                            June 02, 2025

                            Lead Product(s) : BNT327,Etoposide,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $11,100.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Indiana University

                            Country arrow
                            EPSC
                            Not Confirmed

                            Indiana University

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encoberminogene Rezmadenovec,Etoposide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Exelixis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Maintenance Zanzalintinib With Etoposide After HDCT in GCT

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 22, 2025

                            Lead Product(s) : Encoberminogene Rezmadenovec,Etoposide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Exelixis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth